Files registration statement with the Securities and Exchange Commission for a proposed secondary offering of 2,610,000 shares of common stock. Of the shares, 2,509,344 would be offered by the company and 100,656 would be offered by selling shareholders. The company intends to use about $3 mil. of the net proceeds "to automate and expand manufacturing systems," approximately $4 mil. for sales and marketing expansion, $500,000 for capital equipment and the remainder for "working capital and general corporate purposes." Pacific Growth Equities is underwriting. The Portland, Oregon firm began marketing its Biojector 2000 CO[2], powered jet injection system for needle- free drug delivery in the U.S in January. Cleared via 510(k) in 1987, the device sells for $995 and expels medication "rapidly through a precision molded, small diameter orifice in a thin stream at pressures sufficient to penetrate the skin and force the medication into the tissue at the desired level," according to the prospectus. The firm also is developing a "self-injection" system for insulin delivery under an agreement with Lilly ("The Gray Sheet" May 25, 1992, p. 17).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.
Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.